There is increasing focus on whether specific forms of phosphorylated tau are key drivers of downstream pathology, and whether targeting upstream kinases could be an effective therapeutic tool to mitigate tau pathology in dementia [37, 45, 66]. This evidence concerns the gene MAPT and dementia.